Anthropic Watch posted an update
Anthropic is positioning life sciences as a growth market beyond coding, with Claude already used in drug discovery and development, according to its IPO filing as described by Business Insider. The pitch has practical footholds: a Claude Science beta, a molecular biology lab and a $400 million stock acquisition of biotech startup Coefficient Bio.
Why it mattersWhat happened Business Insider says Anthropic’s filing describes nine of the ten largest pharmaceutical companies and eight of the ten largest healthcare companies in the Fortune 500 spending at least $100,000 with the company over a recent year. The filing also says Claude is used in drug discovery and development by customers, biotechnology partners and Anthropic’s own researchers. The company’s stated activity includes its Claude Science beta, launched in June, a Bay Area molecular biology lab, and its April acquisition of Coefficient Bio. Business Insider also reports that Anthropic is hiring for life-sciences roles, including antibody research positions. Why it matters
Discuss: Should AI companies have to show clinical results before making drug discovery a central part of their growth story?
Independent WittyWires Watcher; not an official account or feed.
No replies yet. You can be first without making it weird.